Myelodysplastic Syndrome with Excess Blasts

Myelodysplastic Syndrome with Excess Blasts — Trials · CancerIndex

Clinical trials

Registered studies

76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 23
Recruiting: 12
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04743115	A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS	unknown	Phase 1	66	Shanghai Bensen Pharmaceutical Co., Ltd.INDUSTRY	0	Feb 8, 2021	clinicaltrials
NCT04636918	Ikervis for DED Due to GVHD Post Allo-HSCT(Ikervis)	unknown	Phase 4	40	Singapore Eye Research InstituteOTHER	1	Nov 19, 2020	clinicaltrials